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Objective: Deficits in motor inhibition may contribute to impulsivity and irritability in 
children with bipolar disorder (BPD).  Therefore, studies of the neural circuitry engaged during 
failed motor inhibition in pediatric BPD may contribute to our understanding of the 
pathophysiology of the illness.  We tested the hypothesis that children with BPD and controls 
would differ in ventral prefrontal cortex (vPFC), striatal, and anterior cingulate activation 
during unsuccessful motor inhibition.  We also compared activation in medicated vs. 
unmedicated children with BPD, and in children with BPD and ADHD (BPD+ADHD) vs. 
those with BPD but without ADHD (BPD-ADHD).   
 
Method: Event-related fMRI study comparing neural activation in children with BPD and 
controls while they performed a motor inhibition task.  The sample included 26 children with 
BPD (13 unmedicated, 15 with ADHD) and 17 age, gender, and IQ matched controls.  
 
Results: On failed inhibitory trials, controls showed greater bilateral striatal and right vPFC 
activation than did patients.  While our findings were somewhat more prominent in 
unmedicated than medicated, patients, and in BPD+ADHD than BPD-ADHD, the findings did 
not differ significantly (?) among these subgroups of children with BPD.  
 
Conclusions: Compared to controls, children with BPD may have deficits in their ability to 
engage striatal structures and right vPFC during unsuccessful inhibition. (this reads 
confusingly to me—they’re deficient in their capacity to engage structures when they’re 
behaviorally unsuccessful? Perhaps reword?)  Further research is needed to determine whether 
these deficits play a role in the emotional and behavioral dysregulation characteristic of BPD.  
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Introduction 
Deficits in motor inhibition might produce symptoms of impulsivity and affective 
aggression in pediatric BPD (1, 2) while also contributing to diagnostic confusion between 
attention deficit hyperactivity disorder (ADHD) and BPD (3). The neural circuitry engaged 
during unsuccessful motor inhibition in pediatric bipolar disorder (BPD) is therefore of 
interest.  Research on the pathophysiology of these shared motor symptoms could identify 
common and distinct neural mechanisms between ADHD and BPD.  Finally, motor inhibition 
is mediated by the ventral prefrontal cortex (vPFC), striatum, and anterior cingulate, areas 
implicated in the pathophysiology of BPD (4-12). 
The current study selected regions of interest (ROIs) based on studies implicating 
common brain regions in BPD and motor inhibition. fMRI studies in adult BPD found patient-
control differences in vPFC activation during various tasks (13, 14) (15, 16).  One study in 
children with both BPD and a family history of the illness found that, compared to controls, 
patients had increased vPFC activation while viewing emotional pictures or performing a 
spatial working memory task(17).  In the same study, children with BPD had greater anterior 
cingulate activation than controls during the spatial working memory task, consistent with 
fMRI(18, 19) studies in bipolar adults.  With regard to the striatum, four studies in BPD (two 
of adults, two of youth) reported increased activation in patients vs. controls.   
We studied vPFC, striatal, and cingulate activation in children with BPD who 
performed an event-related version of the stop signal task, a motor inhibition paradigm used to 
study ADHD (20).  Because the failure to appropriately inhibit a motor response is an 
important symptom in pediatric BPD, we were particularly interested in circuitry engaged 
during unsuccessful motor inhibition.  The stop signal paradigm includes two features that 
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facilitate the study of such circuitry.  First, the paradigm adjusts difficulty based on subject 
performance, so that all subjects fail to inhibit on approximately 50% of inhibitory trials.  This 
ensures a relatively large number of unsuccessful inhibitory (“stop incorrect”) trials to contrast 
with both successful inhibitory (“stop correct”) trials and go trials.   Second, all trials begin 
with a go signal, followed in approximately 25% of trials, by a stop signal.  Thus, the contrast 
of “stop incorrect” vs. “go” trials controls for the presence of both a motor response and a go 
signal, thus isolating circuitry engaged during failed motor inhibition. In addition, the “stop 
correct” vs. “stop incorrect” contrast examines the circuitry engaged during successful 
inhibition.  This contrast controls for stimulus properties (i.e. the presence of both go and stop 
signals), but not for the presence or absence of a motor response. 
In research in this area, two potential confounds deserve particular attention: 
medication and comorbid ADHD.  We recruited enough children with BPD to compare neural 
activation in medicated vs. unmedicated patients, and in those with vs. without ADHD. Such 
comparisons are rare in the literature. One fMRI study of adult bipolar patients compares 
unmedicated to medicated patients (REF Caliguiri).  All other published fMRI studies in BPD 
include predominantly medicated subjects (NEED REFS).  Similarly, while studies find 
comorbid ADHD in at least 60% of children with BPD (REF), previous fMRI studies have not 
compared activation in bipolar children with and without comorbid ADHD. 
We used rapid event-related fMRI and the stop signal task to study motor inhibition in 
children with BPD.  Given the clinical importance of failed motor inhibition in pediatric BPD, 
we focused on circuitry engaged during unsuccessful inhibition.  Because the vPFC, anterior 
cingulate, and striatum have been implicated in both motor inhibition and BPD, we 
hypothesized that patients and controls would differ in activation in these regions.  In addition, 
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we compared activation in medicated patients vs. unmedicated patients, and in bipolar patients 
with ADHD (BPD+ADHD) vs. those without ADHD (BPD-ADHD).   
 
Methods 
Subjects  
The patient group consisted of XX youth recruited via advertisements to patient 
advocacy groups.  All patients met DSM-IV diagnostic criteria for BPD and exhibited the 
narrow phenotype of BPD, in that each had a history of at least one hypomanic or manic 
episode meeting full duration criteria and including expansive, elevated mood(3).  Patients 
were excluded if they had severe Pervasive Developmental Disorder, substance use within the 
past 3 months, or IQ<70. A best-estimate diagnostic approach was used, as described 
elsewhere (give ref), integrating data from the Schedule for Affective Disorders and 
Schizophrenia (K-SADS-PL(21); parent and child were interviewed separately by clinicians, 
master’s level or above, with kappa > 0.9), treating physicians, and medical records. Comorbid 
diagnoses were assigned only if the patient met criteria for the comorbid diagnosis while 
euthymic.  Thus, the diagnosis of comorbid ADHD could not be due to the overlap between 
symptoms of ADHD and those of mania or hypomania. 
Of the XX patients scanned, data from 26 were usable.  A priori exclusion criteria 
included inadequate task performance (i.e., < 65% correct on go trials) or excessive movement 
(> 2.5 mm in any plane).  Data were not usable for YY patients, and the clinical data provided 
below includes only the 26 patients with usable scanning data. 
Comorbid disorders were common (Table 1).  Fifteen patients (58%) had a comorbid 
diagnosis of ADHD.  Clinicians completed mood ratings (Young Mania Rating Scale 
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(YMRS)(22) and Children’s Depression Rating Scale (CDRS)(23)) within 24 hours of 
scanning (Table 1).  Five patients were hypomanic (YMRS score>12 but<=20) and the 
remaining 21 were euthymic.  Thirteen patients (50%) were medicated (for medication types, 
see Table 1). 
Controls comprised 26 youth with no K-SADS-PL(24) diagnosis, no DSM-IV 
diagnoses in first-degree relatives (family history was ascertained by parent interview), no use 
of psychoactive substances, and IQ>70.  Of the 26 scanned controls, data from 17 were usable.   
Groups did not differ significantly on age, gender, or IQ(25)  (Table 1).  The study was 
approved by the NIMH IRB; participants and a parent provided written informed 
consent/assent.  
 
Behavioral Task 
 The task was based on previously published work (26, 27).  On all trials, a white 
fixation cross appeared for 500 ms; it was replaced by an “X” or “O” “go-signal” for 1000 ms 
(Fig.1). Using a button-box, subjects pressed “1” for “X” and “2” for “O”.  Subjects were told 
to respond within 1000 ms, unless the background changed to red, which occurred on 25% of 
the trials (i.e. stop trials). In these instances, they were instructed not to press either button.  
 On the first stop trial, the stop signal appeared 250 ms after the go-signal.  Subsequent 
stop-signal timing was based on subject performance.  If the subject successfully inhibited, the 
next stop signal appeared 50 ms later, making inhibition more difficult; if the subject failed to 
inhibit, the signal appeared 50 ms earlier, making inhibition easier.  Trials were separated by 
750 ms. 
 Prior to scanning, subjects were trained to achieve a mean reaction time (RT) less than 
1000 msec on “go” trials and successful inhibition on 40-60% of stop trials.  Subjects received 
 7 
feedback after each block during scanning; they were told to decrease their reaction time if the 
mean exceeded 1000 ms. 
 
Scanning acquisition 
Scanning occurred in a GE Signa 3Tesla magnet at NIMH.  Head movement was 
restricted with padding; images were presented via Avotec Silent Vision Glasses (Stuart, FL).   
Gradient echo planar images (EPI) were acquired after sagittal localization and manual 
shimming.  EPI images used 23 contiguous 5mm axial slices, parallel to the AC-PC line, and 
EPI single-shot gradient echo T2* weighting (matrix 64x64; TR =2000 ms; TE =40 ms; Field 
of View =240 mm; voxels 3.75x3.75x5 mm).   
Subjects completed four runs, each with 32 go, 16 stop, and 16 blank fixation trials 
distributed randomly throughout each block.  Blank fixation trials were included, based on the 
“rapid-event-related” paradigm of Holmes and Friston (REF), and Zarahn (REF), to allow 
deconvolution of unique events occurring close in time.  These trials provide an implicit 
statistical baseline (REF Zarahn).   
A high resolution T1 weighted anatomical image was acquired for spatial 
normalization.  A standardized magnetization prepared gradient echo sequence was used (180 
1 mm sagittal slices; FOV = 256; NEX = 1; TR = 11.4 ms; TE = 4.4 ms, matrix = 256x256; TI 
= 300 ms; bandwidth = 130 Hz/pixel, 33kHz/256 pixels). 
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Data Analysis 
Behavioral data 
 The following were recorded during scanning: RT and accuracy on go trials (GoRT), 
accuracy on stop trials, and inhibit delay (i.e. interval between the onsets of the go and stop 
signals).  The stop signal reaction time (SSRT), or speed of inhibition, was calculated.  When a 
subject inhibits successfully on 50% of stop trials, the SSRT is the mean GoRT minus the 
mean inhibit delay (27, 28).  Since subjects’ accuracy on stop trials may deviate from 50%, an 
interpolation algorithm was used to calculate SSRT: the mean stop signal delay was subtracted 
from the GoRT at the xth  percentile, where x is the subject’s % accuracy on stop trials.   
 
Imaging data 
Primary analyses 
 
Analyses were conducted with SPM99b.  Preprocessing included slice time correction, 
motion correction, and spatial normalization.  At the subject level, event-related response 
amplitudes were estimated using the General Linear Model (GLM).  Event types included 
unsuccessful stop (“stop-incorrect”), “correct-go” (“go”; N.B. hereinafter, “go” refers only to 
correct go trials), and successful-stop (“stop-correct”) trials. A rectangular pulse (2250 msec, 
the length of each event) was used to model each event, convolved with the hemodynamic 
response function provided by SPM.  A high pass filter of .024 Hz was applied.   
Contrast images were created for each subject using pairwise comparisons of event-
related response amplitudes.  The primary analysis was activation on stop-incorrect vs. go 
trials, in BPD vs. controls.  We also compared activation on stop-correct vs. stop-incorrect 
trials, in BPD vs. controls.  For both contrasts, subsequent analyses compared medicated 
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patients to controls, unmedicated patients to controls, and unmedicated to medicated patients.  
In addition we compared BPD+ADHD to controls, BPD-ADHD to controls, and BPD+ADHD 
to BPD–ADHD on both contrasts.    
Prior to group analysis, each contrast image was proportionally scaled.  These 
normalized contrast images were smoothed using an isotropic Gaussian kernel (FWHM = 11.4 
mm).  A group level random effects model was employed to provide population level-
inference.   
A small volume corrected, ROI analysis was used: the ROIs were bilateral vPFC, 
striatum (accumbens, caudate, putamen), and anterior cingulate. Significance was set at p<.05.  
ROI templates were defined on the canonical single subject’s structural MRI images supplied 
by SPM99.  Templates were defined using MedEx software, drawn by hand in the coronal 
plane, and applied to all normalized brains at the group level.  Coordinates are in Montreal 
Neurological Institute (MNI) space.  The cingulate, putamen, and caudate were ascertained 
from standard anatomical criteria.(29-32). The accumbens was identified at the inferior 
junction between the head of the caudate and putamen.  It was delimited superiorly by a line 
connecting the inferior corner of the lateral ventricle and the inferior point of the internal 
capsule abutting the accumbens, and laterally by a vertical line passing from the latter 
point(33).  The vPFC boundaries were defined as the last slice with the anterior horizontal 
ramus, the last slice containing the olfactory sulcus, anterior horizontal ramus, and the 
olfactory sulcus (Monk, 2003; McClure Bio Psych gender paper, 2004).  
 
Results 
Behavioral Data 
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 There were no between-group differences in mean inhibit delay, go RT, stop accuracy, 
or SSRT, but patients had significantly lower go accuracy than controls (Table 2).  In the fMRI 
analysis, to control for between-group differences in stop and go accuracy, only correct go 
trials were used; stop-correct and stop-incorrect trials were analyzed separately.  There were no 
significant behavioral differences between unmedicated and medicated patients, or between 
BPD+ADHD vs. BPD-ADHD. 
 
Imaging data 
Stop incorrect vs. go 
 All bipolar patients vs.  controls:  Bipolar patients did not show increased activation 
relative to controls in any ROI.  However, controls had greater activation than patients in 
caudate, putamen, accumbens, and vPFC (Table 3).    
 Effect of medication: There were no significant differences between unmedicated and 
medicated patients in any ROI.  The comparisons of controls vs. medicated patients, and of 
controls vs. unmedicated patients, yielded similar results.  That is, controls had greater 
activation than unmedicated patients in accumbens, caudate, and putamen, with a trend toward 
increased activation in vPFC (Table 3). Similarly, controls had greater activation than 
medicated patients in left accumbens, left caudate, and right vPFC, with a trend toward greater 
activation in right accumbens (Table 3).   
 Effect of comorbid ADHD: There were no significant differences between BPD+ADHD 
and BPD-ADHD in any ROI. Controls had greater activation than did BPD+ADHD in striatum 
(bilateral accumbens, caudate, and putamen), as well as bilateral anterior cingulate and vPFC 
(Table 3).  The differences between controls and BPD-ADHD were limited to the striatum, 
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with controls having greater activation in bilateral accumbens and left caudate, with a trend 
toward greater activation in left putamen (Table 3). 
 
Stop correct vs. stop incorrect 
 All bipolar patients vs. controls:  With all bipolar patients included in the analysis, 
patients had increased activation compared to controls in the right vPFC (Table 3).  Patients 
and controls did not differ on any other ROI.   
 Effect of medication: ,There were no significant differences between medicated patients 
and controls in any ROI.  However, unmedicated patients had significantly greater activation 
than controls in bilateral accumbens, caudate, and putamen, in right OFC, and in right anterior 
cingulate (Table 4).  Similarly, unmedicated patients had significantly greater activation than 
did medicated patients in bilateral accumbens, left putamen, and right caudate (Table 4). 
 Effect of comorbid ADHD: , There were no significant differences between BPD–
ADHD and controls in any ROI.  However, BPD+ADHD had greater activation than controls 
in right accumbens, right putamen, and right vPFC (Table 4).  BPD+ADHD also had greater 
activation than BPD-ADHD in bilateral accumbens, putamen, and vPFC, and left caudate 
(Table 4). 
 
Across-condition comparison at peak voxels 
 These results indicate greater striatal and right vPFC activation in controls than patients 
in the stop incorrect vs. go contrast, and greater striatal and right vPFC activation in patients 
than controls in the stop correct vs. stop incorrect contrast.  These findings could both be due to 
increased striatal and vPFC activation in controls, compared to patients, on incorrect stop trials.  
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To explore this possibility, for the right vPFC and each striatal ROI, we identified the voxel 
showing the greatest between-group difference in the stop incorrect vs. go contrast. For that 
voxel, we plotted the mean beta on the stop correct vs. fixation, stop incorrect vs. fixation, and 
go vs. fixation contrasts. Blank fixation trials were used so that the responses to the other 
conditions could be estimated efficiently (Friston, Zarahn, Josephs et al, NeuroImage 10, 
607—619, 1999). This yielded a series of histograms, one for each striatal area and one for 
right vPFC. Each histogram showed a similar pattern: i.e., controls showed significantly 
greater activation than patients on stop incorrect trials (see Fig. X).  
 
Discussion 
 Given the importance of failed inhibition in the clinical presentation of pediatric BPD, 
we used rapid event-related fMRI to study the neural circuitry engaged during unsuccessful 
inhibitory trials.  On such trials, controls showed greater bilateral striatal and right ventral 
prefrontal activation than did patients.  While our findings were somewhat more prominent in 
unmedicated, compared to medicated, patients, and in BPD+ADHD, compared to BPD-
ADHD, the findings did not differ significantly (?) among these subgroups of children with 
BPD.  
Whereas SSRT did not differ between groups in these small samples, data from a larger 
sample indicate a trend suggesting that bipolar patients may be slower than controls to inhibit 
prepotent responses (34).  Moreover, data from related tasks indicate that children with BPD 
have deficits in motor regulation (34).  Neuroimaging and basic research implicate the striatum 
in the learning and execution of motor programs (35).  Recent research in adults indicates 
striatal engagement with increasing neurocognitive load (36), and animal research suggests that 
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striatal dopaminergic neurons produce error signals(37).  (this paragraph doesn’t flow—
perhaps rewrite the preceding 3 sentences to soften the jump from deficient motor regulation to 
striatal function) Data presented here and elsewhere(34) suggest that motor inhibition deficits 
in pediatric BPD may reflect a failure to engage the striatum appropriately during failed 
inhibition.   
Our finding contrasts with four studies showing increased, rather than decreased, 
striatal activation in patients with BPD vs. controls(38-41).  Various factors could account for 
such inconsistencies.  None of the studies finding striatal hyper-activation used a motor 
inhibition paradigm, although one(42) did employ an interference task.  Moreover, we 
examined neural activation on a trial-by-trial basis in relation to subject behavior unlike prior 
studies in which behavioral data were not obtained(43, 44), block designs were used(45), or 
ceiling-effects occurred (46).  While the data presented here indicate decreased striatal 
activation in patients vs. controls during failed inhibition, we have observed increased striatal 
activation in patients vs. controls in a different psychological context (unpub data); a similar 
phenomenon has been reported with regard to dorsolateral prefrontal function in patients with 
schizophrenia (Callicott, AJP 2003). Thus, striatal dysfunction in BPD may manifest 
differently across different situations. 
 These results may elucidate how striatal dysfunction contributes to disinhibition and 
other affective and behavioral impairments in pediatric BPD.  Patients with BPD have motor 
abnormalities in both depressed and manic states i.e., hyperactivity in mania and hypo- or 
hyperactivity in depression.  Also, impulsivity is an important clinical feature of BPD, across 
mood states and between episodes.  In adults with BPD, impulsivity is frequently associated 
with risky behavior such as substance abuse, present in 60% of adults with BPD (47).  In 
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children with BPD, impulsivity is associated with irritability, and both are impairing across 
mood states (48).  Data in control children suggest that irritability and decreased motor 
inhibition may be related mechanistically: in controls, impaired motor inhibition (i.e., increased 
SSRT) is associated with increased intensity of experienced anger(49).  Speculatively, we 
suggest that the impulsivity seen in patients with BPD across the developmental spectrum is 
associated with failure to engage the striatum in situations requiring motor inhibition.  If so, 
interventions that facilitate striatal engagement in such contexts might provide avenues to 
decrease impulsivity in BPD. 
 We found between-group differences in the right vPFC that, although less robust and 
consistent than those in the striatum, followed a similar pattern, in which controls showed 
greater vPFC activation than patients on failed inhibitory trials.  The congruence of our vPFC 
and striatal findings is consistent with nonhuman primate research indicating significant 
structural and functional connections between the two regions (REF).  
With one exception (Caligiuri), fMRI studies of neither children nor adults with BPD 
have examined the impact of either medication or comorbid illnesses on neural activation.  
Using a simple motor task, Caligiuri et al reported increased cortical and subcortical activation 
in bipolar adults that was normalized by medication.  We also found that medication dampened 
patient-control differences, suggesting that studies of medicated patients might be prone to 
Type II, rather than Type I, errors.  With regard to comorbid ADHD, we found that bipolar 
children with or without ADHD differed from controls in striatal activation during failed 
inhibition (i.e., on the stop incorrect vs. go contrast).  However, on the stop correct vs. stop 
incorrect contrast, BPD+ADHD, but not BPD-ADHD, differed from controls, and 
BPD+ADHD differed from BPD-ADHD in activation on several ROIs. Thus, the impact of 
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comorbidity on fMRI results in pediatric BPD can be complex, varying from contrast to 
contrast and, possibly, with the behavioral paradigm.  Finally, it is unclear whether the 
pathophysiology of ADHD symptoms is the same in children with BPD and children with 
ADHD only or, alternatively, whether ADHD in children with BPD is a phenocopy of the more 
common forms of ADHD(50).  Indeed, whereas we found increased right vPFC activation in 
BPD+ADHD vs. controls on the stop correct vs. stop incorrect contrast, a study in ADHD 
children found that patients, compared to controls, had significantly reduced activation in the 
right inferior frontal PFC during successful inhibition (Rubia, AJP, 2005). CHECK THIS 
Follow-up research should compare fMRI data from children with ADHD only to children with 
BPD. Also, further study is needed to ascertain the possible impact of mood state on our 
results.  Since 18 of 22 patients were euthymic, the deficits we identified may be trait-related, 
but more definitive work is needed.  
In sum, our data indicate that, compared to controls, children with BPD may have 
deficits in their ability to engage striatal structures and right vPFC during unsuccessful 
inihibition.  These results may give clues to the pathophysiology of disinhibition and 
impulsivity in BPD.   
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Table 1. Demographic and clinical characteristics                          
Characteristic Controls (N=17) Bipolar (N=26) 
Gender:  % male (N)        53 (9)  46 (12) 
Age (years; mean + SD)       14.6+1.8         13.6+2.6 
WASI FSIQ (mean + SD)        109.9 + 12.3 (N=15) 106.7+13.0 (N=22)  
Bipolar I: % (N) --  91.7 (22) (two missing) 
Bipolar II: % (N) --  8.3 (2) 
Young Mania Rating Score  
(mean + SD)  
--  7.3 + 5.5 
Children’s Depression Rating Score 
(mean + SD) 
--  24.3 + 6.1 
# Comorbid diagnoses (mean + SD)  --         1.4+1.0 (two missing) 
  Comorbid ADHD1: % (N) --  57.7 (15) 
  Comorbid anxiety disorder: % (N) --  54.2 (13) (two missing) 
  Comorbid ODD/CD2: % (N) --  37.5 (9) (two missing) 
  Unmedicated: % (N)   --          50% (13) 
#  of Medications (mean + SD)3 --  3.2 + 1.1 
  Atypical Antipsychotic: % (N) --  84.6 (11) 
  Lithium: % (N) --  46.2 (6) 
  Anti-Epileptic Drug (AED)4: % (N)  --  84.6 (11) 
  Antidepressant: % (N) --  30.8 (4) 
  Stimulant: % (N) --  30.8 (4) 
  Other: % (N) --  15.4 (2) 
1= Attention deficit hyperactivity disorder; 2= Oppositional defiant disorder or conduct 
disorder; 3=Only children on medication are included in this analysis; 4=includes 
oxcarbamazepine, topiramate, lamotrigine, carbamazepine, sodium valproate, clonazepam  
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Table 2.  Performance on the stop signal task during scanning 
 
 
 Variable (mean + SD) Controls (N=17) BPD (N=26) t df p 
% accurate go  93.8 + 6.2   85.8 + 11.3  3.0  40.1  .005 
% accurate stop  54.0 + 11.9   50.9 + 7.7  0.94  25.6  NS 
Go reaction time 
(msec) 
 738.5 + 135.0   733.6 + 87.4   0.13  25.4 NS 
Inhibit delay* (msec)  508.7 + 138.1   488.0 + 90.8  0.58  39 NS 
SSRT** (msec)  229.6 + 52.3  216.3 + 47.4   0.84  38 NS 
 
* Inhibit delay= interval between onset of go and onset of stop signals.  
** SSRT= stop signal reaction time.  See text for method of calculation. 
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Table 3.  Significant between-group activations in stop incorrect vs. go contrast in regions 
of interest 
GROUPS Region L/R voxels x y z t p 
C vs. All BPD  accumbens L 117 -10 14 -2 4.05 .001 
 caudate L 395 -10 12 0 4.22 .002 
 putamen L 250 -14 16 2 3.74 .008 
 vPFC R 312 32 28 -6 3.24 .034 
 accumbens R 131 12 14 -8 3.54 .005 
 caudate R 468 12 12 0 3.03 .041 
 putamen R 270 18 16 -6 3.23 .027 
         
C vs. unmed BPD accumbens L 127 -10 14 -2 4.09 .001 
 caudate L 463 -10 12 0 4.21 .002 
 putamen L 328 -14 16 2 4.15 .003 
 vPFC R 190 22 22 -10 2.96 .061 
 accumbens R 145 12 14 -8 3.89 .002 
 caudate R 645 18 18 -4 3.25 .001 
 putamen R 285 18 14 -8 3.66 .010 
         
C vs. med BPD accumbens L 77 -8 14 -2 2.97 .021 
 caudate L 129 -10 12 0 3.06 .034 
 vPFC R 355 34 26 -8 3.37 .026 
 accumbens R 77 10 14 -6 2.45 .057 
         
C vs. BPD+ADHD  vPFC L 232 -34 24 0 3.24 .040 
 ant cingulate L 800 4 40 12 3.58 .027 
 accumbens L 96 -10 14 -2 3.67 .004 
 putamen L 343 -14 14 2 3.60 .011 
 vPFC R 354 34 32 -6 3.75 .011 
 ant cingulate R 1167 8 40 12 3.73 .016 
 accumbens R 123 12 12 -4 3.29 .009 
 caudate R 562 12 12 0 3.05 .039 
 putamen R 395 28 18 6 3.34 .021 
         
C vs. BPD-ADHD accumbens L 112 -8 14 0 3.30 .010 
 caudate L 206 -8 12 0 3.44 .014 
 putamen L 92 -14 16 2 2.83 .062 
 accumbens R 114 12 14 -8 2.80 .028 
ant cingulate= anterior cingulate; vPFC= ventral prefrontal cortex; C=controls; BPD=patients 
with bipolar disorder; med=medicated; unmed=unmedicated; BPD+ADHD=patients with BPD 
and ADHD; BPD-ADHD=patients with BPD, without ADHD 
Coordinates are in MNI space.  Significance is defined as p<.05 on a small volume corrected, 
region of interest analysis. 
Note: Many areas of activation had multiple significant maxima within the cluster noted.  In 
the interest of space, only the maximum with the highest t value is reported for each cluster. 
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Table 4.  Significant between-group activations in stop correct vs. stop incorrect contrast 
in regions of interest 
 
GROUPS Region L/R voxels x y z t p 
All BPD vs. C vPFC R 335 34 26 -6 3.30 .032 
         
Unmed  BPD vs. C accumbens L 65 -14 4 -6 2.60 .048 
 caudate L 294 -10 10 8 3.02 .038 
 putamen L 474 -14 10 2 3.13 .035 
 vPFC R 417 34 24 -6 4.04 .006 
 ant cingulate R 507 10 14 26 3.26 .048 
 accumbens R 145 16 16 -8 3.03 .017 
 caudate R 551 12 12 20 3.26 .026 
 putamen R 445 26 18 -6 3.11 .036 
         
Unmed BPD vs. med BPD accumbens L 36 -14 4 -12 2.79 .033 
 putamen L 661 -26 10 4 3.04 .042 
 ant cingulate R 179 10 14 26 3.46 .031 
 accumbens R 108 10 4 -6 2.67 .038 
 caudate R 357 14 12 22 3.70 .009 
         
BPD+ADHD vs. C vPFC R 412 34 26 -6 3.78 .010 
 putamen R 283 30 18 4 3.01 .045 
         
BPD+ADHD vs.  
BPD-ADHD 
vPFC L 106 -24 20 -2 3.12 .053 
 accumbens L 106 -14 4 -6 3.35 .009 
 caudate L 65 -12 16 -2 2.94 .044 
 putamen L 740 -16 10 -4 3.61 .011 
 vPFC R 362 30 22 -6 3.07 .050 
 accumbens R 111 14 12 -12 3.20 .011 
 putamen R 790 34 -8 2 4.12 .003 
ant cingulate= anterior cingulate; vPFC= ventral prefrontal cortex; C=controls; BPD=patients 
with bipolar disorder; med=medicated; unmed=unmedicated; BPD+ADHD=patients with BPD 
and ADHD; BPD-ADHD=patients with BPD,without ADHD 
 
Coordinates are in MNI space.  Significance is defined as p<.05 on a small volume corrected, 
region of interest analysis. 
 
Note: Many areas of activation had multiple significant maxima within the cluster noted.  In 
the interest of space, only the maximum with the highest t value is reported for each cluster. 
 24 
Fig. 1a. Activation on stop incorrect vs. go contrast, controls vs. all bipolar patients. Data 
shown at p<.005, whole brain uncorrected, for purposes of presentation.  Peak activation  in 
left caudate, x=-10, y=12, z=0, t=4.22, kE=395, p=.002. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig. 1b. Activation at -10, 12, 0 in controls and all bipolar patients on the stop correct vs. 
fixation, stop incorrect vs. fixation, and go correct vs. fixation contrasts.  
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